Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
企業コードCAI
会社名Caris Life Sciences Inc
上場日Jun 18, 2025
設立日2020
最高経営責任者「CEO」Mr. David Dean Halbert
従業員数- -
証券種類Ordinary Share
決算期末Jun 18
本社所在地750 West John Carpenter Freeway
都市IRVING
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号75039
電話番号18667718946
ウェブサイトhttps://www.carislifesciences.com/
企業コードCAI
上場日Jun 18, 2025
設立日2020
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし